首页 | 本学科首页   官方微博 | 高级检索  
检索        

不同剂量瑞舒伐他汀对病窦综合症患者起搏治疗后阵发房颤的影响
引用本文:位少彬,蔡尚郎,王茂敬,纪阳.不同剂量瑞舒伐他汀对病窦综合症患者起搏治疗后阵发房颤的影响[J].心血管康复医学杂志,2013(3):272-275.
作者姓名:位少彬  蔡尚郎  王茂敬  纪阳
作者单位:青岛大学医学院附属医院心内科,山东青岛266003
摘    要:目的:观察不同剂量瑞舒伐他汀对病窦综合征(SSS)患者起搏治疗后阵发房颤的影响。方法:选择SSS伴阵发房颤(PAF)患者54例,行双腔起搏治疗后随机分为常规治疗组、瑞舒伐他汀低剂量(低剂量组)和瑞舒伐他汀高剂量(高剂量组),每组18例。12个月疗程后比较3组患者高敏C反应蛋白(hsCRP)水平、左房内径(LAD)和房颤(AF)发生情况。结果:治疗12个月后,与常规治疗组相比,他汀低、高剂量组血浆hsCRP(4.79±1.62)mg/L比(3.37±1.24)mg/L、(3.31±1.21)mg/L]水平明显降低,AF发生次数(16.17±4.89)次/年比(7.39±2.68)次/年、(7.44±2.68)次/年]、AF负荷(30.61±5.65)h/年比(6.33±2.57)h/年、(6.44±2.60)h/年]明显减少,LAD(40.22±4.91)mm比(36.39±3.29)mm、(36.28±3.53)mm]显著减小(P均<0.05),高、低剂量组疗效上差异无显著性。结论:瑞舒伐他汀可以改善起病窦综合征伴阵发房颤患者双腔起搏治疗后心房重构,减少房颤发生,其疗效与剂量无相关性。

关 键 词:心脏起搏器  人工  心房颤动  病窦综合征  瑞舒伐他汀

Influence of different doses rosuvastatin on paroxysmal atrial fibrillation in patients with sick sinus syndrome after pacemaker implantation
WEI Shao-bin,CAI Shang-lang,WANG Mao-jing,JI Yang.Influence of different doses rosuvastatin on paroxysmal atrial fibrillation in patients with sick sinus syndrome after pacemaker implantation[J].Chinese Journal of Cardiovascular Rehabilitation Medicine,2013(3):272-275.
Authors:WEI Shao-bin  CAI Shang-lang  WANG Mao-jing  JI Yang
Institution:WEI Shao-bin, CAI Shang-lang, WANG Mao-jing, Jl Yang(Department of Cardiology, Affiliated Hospital of Medical College of Qingdao University, Qingdao, Shandong, 266003, China)
Abstract:Objective:To observe influence of different doses rosuvastatin on paroxysmal atrial fibrillation(PAF)in patients with sick sinus syndrome(SSS)after pacemaker implantation.Methods:A total of 54patients with SSS complicated PAF were selected,randomly and equally divided into routine treatment group,low dose rosuvastatin group(low dose group) and high dose rosuvastatin group(high dose group) after dual-chamber pacemaker implantation.Based on routine treatment,low dose and high dose groups received rosuvastatin 10mg,20mg respectively.After 12-month treatment,level of high sensitive C reactive protein(hsCRP),left atrial diameter(LAD) and incidence of atrial fibrillation(AF) were compared among three groups.Results:Compared with routine treatment group after 12-month treatment,there were significant decrease in hsCRP level (4.79±1.62) mg/L vs.(3.37± 1.24) mg/L,(3.31±1.21) mg/L ],AF times (16.17±4.89) times/years vs.(7.39±2.68) times/years,(7.44± 2.68) times/year ],AF load (30.61±5.65) h/years vs.(6.33±2.57) h/years,(6.44±2.60) h/years ] and LAD (40.22±4.91) mm vs.(36.39±3.29) mm,(36.28±3.53) mm ] in low dose group and high dose group,P 0.05all.There were no significant difference in curative effect between low dose group and high dose group.Conclusion:Rosuvastatin can improve atrial remodeling and decrease incidence of atrial fibrillation in patients with sick sinus syndrome complicated paroxysmal atrial fibrillation after dual chamber pacemaker implantation,and its curative effect is not related with dose.
Keywords:Pacemaker  artificial  Atrial fibrillation  Sick sinus syndrome  Rosuvastatin
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号